Clinical trials in Vila Nova De Gaia – page 56

680 clinical trials in Vila Nova De Gaia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Vila Nova De Gaia at a glance

680

clinical trials

Research sites0

Quick filters

680 trials in Vila Nova De Gaia

Open in trial search

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:Bayer AG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Kite Pharma Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Bronchopulmonary dysplasia

Not recruiting

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo

Portugal

Participants:0–17 years
Substances:Mecasermin Rinfabate
Sponsor:Ohb Neonatology Limited

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Isatuximab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Aveo Pharmaceuticals Inc.

Contact Research Centre

Frontotemporal dementia

Not recruiting

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Latozinemab
Sponsor:Alector LLC

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Retifanlimab
Sponsor:Incyte Biosciences International S.a.r.l.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo

Portugal

Participants:0–17 years
Substances:Dupilumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Vila Nova De Gaia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, breast cancer, and multiple myeloma treatments. Studies include evaluations of novel therapies for both early-stage and metastatic conditions.

Advanced Head & Neck Squamous Cell Carcinoma
HER2-positive Breast Cancer
Multiple Myeloma Maintenance Therapy

Research encompasses targeted therapies and combination treatments aimed at improving patient outcomes.

02 Autoimmune Disorders

Comprehensive studies investigating treatments for various autoimmune conditions, including Sjögren's Syndrome and systemic sclerosis. Focus on developing targeted therapies for immune system regulation.

Primary Sjögren's Disease
Diffuse Cutaneous Systemic Sclerosis
Immune Thrombocytopenia

Evaluating novel biological therapies to address complex autoimmune manifestations.

03 Metabolic & Cardiovascular Studies

Research focused on obesity management and cardiovascular health. Studies evaluate new therapeutic approaches for weight management and cardiovascular disease prevention.

Obesity Treatment
Pulmonary Arterial Hypertension
Cardiovascular Risk Management

Investigating innovative treatments to address growing metabolic health challenges.

Back to Portugal All countries